Some studies have shown that a combination therapy involving a TGF-β blocker and EcN could effectively induce tumor suppression and necrosis in subcutaneous tumor-bearing mice, with superior therapeutic outcomes compared to using a TGF-β blocker or EcN alone. The gene discussed is TGFB1; the disease is neoplasm.